Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
119.93
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday
September 24, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
Forecasting The Future: 8 Analyst Projections For BioNTech
September 13, 2024
Via
Benzinga
Market Whales and Their Recent Bets on BNTX Options
September 13, 2024
Via
Benzinga
Unveiling 12 Analyst Insights On BioNTech
August 19, 2024
Via
Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
September 16, 2024
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...
Via
Benzinga
Exposures
COVID-19
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
September 15, 2024
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.
Via
Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...
Via
Benzinga
Why Is Moderna Stock Trading Higher On Monday?
September 09, 2024
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu...
Via
Benzinga
Exposures
COVID-19
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
September 06, 2024
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys.
Via
Benzinga
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
September 03, 2024
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for...
Via
Benzinga
Exposures
COVID-19
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
August 31, 2024
UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and...
Via
Talk Markets
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
August 29, 2024
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...
Via
Benzinga
Exposures
COVID-19
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
August 26, 2024
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season.
Via
Benzinga
Exposures
COVID-19
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
August 22, 2024
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...
Via
Benzinga
Exposures
COVID-19
Product Safety
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
August 19, 2024
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
Via
Benzinga
Topics
ETFs
Exposures
COVID-19
Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
August 19, 2024
FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety...
Via
Benzinga
Exposures
Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
August 19, 2024
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19.
Via
The Motley Fool
Why Pfizer Stock Slumped on Friday
August 16, 2024
Investors were cautiously pessimistic about the latest news coming out of the company's lab.
Via
The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
August 16, 2024
The company is now considering whether it needs to change up the vaccine to pass muster.
Via
Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
August 16, 2024
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve...
Via
Benzinga
Exposures
COVID-19
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
August 13, 2024
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among...
Via
Benzinga
Exposures
COVID-19
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
August 13, 2024
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to...
Via
Benzinga
Exposures
COVID-19
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.
Via
InvestorPlace
Exposures
Product Safety
This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
August 07, 2024
Via
Benzinga
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
August 05, 2024
BNTX earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.